Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The results met or exceeded expectations for safety, lens delivery, and vision performance, representing a key clinical de-risking milestone as the company advances toward subsequent study phases.
Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250, levels consistent with legal blindness. Post-implantation outcomes underscore both the clinical effectiveness and real-world impact of the lens. According to Dr. Rafael Vázquez, principal investigator of the trial, patients who were classified as legally blind can now read, enjoy everyday activities, and drive. “The impact on their independence and sense of freedom has been remarkable,” he said.
Dean Burns, President and CEO of Ocumetics, expressed confidence in the technology, stating, “These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes. Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100% confident in our accommodating intraocular lens technology.”
The Group 1 data met all predefined internal benchmarks, successfully achieving the primary objectives required to progress the clinical program. The results can be summarized as: safety profile met expectations, visual acuity outcomes met and exceeded expectations, and lens delivery system met expectations.
Based on insights from Group 1, Ocumetics has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in Group 2. Manufacturing and testing of optimized lens designs are currently underway, with Group 2 surgeries expected to be scheduled following completion of final lens testing and validation.
The company continues to apply its rapid “win-learn” R&D approach, incorporating surgeon feedback in real time to further optimize performance. “Our Group 1 results clearly demonstrated and confirmed the viability of our accommodating intraocular lens technology,” Burns concluded. “This milestone materially strengthens our clinical foundation and positions Ocumetics to build momentum as we advance into Group 2.”
Ocumetics will host a webinar on February 4, 2026, at 4:00 PM ET to discuss the results and study updates. More information is available at www.ocumetics.com/webinar.
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The company’s accommodating intraocular lens is designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses by allowing the eye’s natural muscle activity to shift focus from distance to near.
